SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001069530-22-000046
Filing Date
2022-09-23
Accepted
2022-09-23 09:05:48
Documents
13
Period of Report
2022-09-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sava-20220922x8k.htm   iXBRL 8-K 86168
  Complete submission text file 0001069530-22-000046.txt   233735

Data Files

Seq Description Document Type Size
2 EX-101.SCH sava-20220922.xsd EX-101.SCH 2914
3 EX-101.DEF sava-20220922_def.xml EX-101.DEF 12969
4 EX-101.LAB sava-20220922_lab.xml EX-101.LAB 17163
5 EX-101.PRE sava-20220922_pre.xml EX-101.PRE 14122
7 EXTRACTED XBRL INSTANCE DOCUMENT sava-20220922x8k_htm.xml XML 6671
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

IRS No.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29959 | Film No.: 221260712
SIC: 2834 Pharmaceutical Preparations